Brought to you by 
China Pharmaceutical acquires CSPC-NBP group of Chinese finished drug makers for HK8.6bn
16 Aug 2012
Executive Summary
China Pharmaceutical Group Ltd. (bulk drug production with a focus on antibiotics) will buy several privately held finished drug manufacturing units grouped under a shell company known as Robust Sun Holdings Ltd. by issuing 1.196bn new shares (78.16% of China Pharmaceutical’s capital) at HK1.60, worth HK1.9bn ($251mm). Including the issue of HK6.7bn in convertible bonds, the price is HK8.6bn. The aggregate net assets of the acquired companies are at least HK950mm.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
China Pharmaceutical acquires CSPC-NBP group of Chinese finished drug makers for HK8.6bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice